This Expanded Access Program is intended to facilitate the availability of OFEV topatients suffering from non Idiopathic Pulmonary Fibrosis-Interstitial Lung Disease (nonIPF-ILD) with a progressive clinical course despite Standard of Care treatment and forwhom no satisfactory authorised alternative therapy exists or who cannot enter a clinicaltrial.
Drug: OFEV
twice daily
Inclusion Criteria:
None
Exclusion Criteria:
- Patients who are eligible for and can participate in an ongoing non Idiopathic
Pulmonary Fibrosis-Interstitial Lung Disease (non IPF-ILD) study will be excluded
from participation in this Expanded Access Program (EAP).
Banner University Medical Center Tucson
Tucson, Arizona, United States
The Lung Research Center, LLC
Chesterfield, Missouri, United States
Glacier View Research Institute
Kalispell, Montana, United States
University of Rochester Medical Center
Rochester, New York, United States
Centra Medical Group
Bedford, Virginia, United States
Inova Fairfax Medical Campus
Falls Church, Virginia, United States